Search for Clinical Trial Results
Myelofibrosis - 57 Studies Found
Status | Study |
Completed |
Study Name: A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2008-07-17 Interventions: Drug: SAR302503 (TG101348) orally administered, once a day |
Recruiting |
Study Name: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis Condition: Myelofibrosis Date: 2016-08-26 |
Active, not recruiting |
Study Name: Lenalidomide for Patients With Myelofibrosis (MF) Condition: Myelofibrosis Date: 2006-07-14 Interventions:
|
Active, not recruiting |
Study Name: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Condition: Myelofibrosis Date: 2012-12-24 Interventions: Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week |
Active, not recruiting |
Study Name: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2012-12-21 Interventions: Drug: Ruxolotinib Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT f |
Active, not recruiting |
Study Name: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Condition: Myelofibrosis Date: 2012-09-14 Interventions:
|
Recruiting |
Study Name: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2016-09-30 Interventions: Other: Hematopoietic Stem Cell Transplant This observational study will compare outcomes of prospectivel |
Completed |
Study Name: Ph II Study of Azacitidine in Myelofibrosis Condition: Myelofibrosis Date: 2007-12-06 Interventions: Drug: Azacitidine 75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle) |
Completed |
Study Name: Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis Condition: Myelofibrosis Date: 2010-06-22 Interventions: Drug: APLIDIN (plitidepsin) Aplidin® (plitidepsin) ly |
Completed |
Study Name: A Phase II Study of CC-5013 in Myelofibrosis Condition: Myelofibrosis Date: 2004-07-12 Interventions: Drug: CC-5013 10 mg orally (2 capsules) daily Other |